City

Beijing (1)

Overall Status

Recruiting (1)

Sign in for free

Phase

phase 2 (1)

Sponsor

Lei Li (1)

Collaborator

Intervention

tislelizumab plus radiotherapy (1)

Study Documents

Intervention Type

combination product (1)

Funder Type

Other (1)

Study Type

Interventional (1)

persistent cervical carcinoma

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus

Recruiting

Recurrent Cervical Carcinoma
+9 more

Tislelizumab plus radiotherapy

Beijing, Beijing, China

Lei Li

Apr 1, 2022